More about GeNeuro’s lead product

GeNeuro has strong expertise in the development of monoclonal antibodies, which are proteins that bind to targets with high specificity. Monoclonal antibodies are produced through genetic engineering and can be designed to recognize and neutralize molecules involved in disease processes. GeNeuro’s lead therapeutic product is a humanized monoclonal antibody, called temelimab, which targets the pathogenic envelope protein encoded by a member of the HERV-W family.